Van ECK Associates Corp Purchases 8,568 Shares of argenx SE (NASDAQ:ARGX)

Van ECK Associates Corp increased its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 22.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,809 shares of the company's stock after acquiring an additional 8,568 shares during the quarter. Van ECK Associates Corp owned approximately 0.08% of argenx worth $28,788,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Stifel Financial Corp boosted its position in shares of argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock worth $4,788,000 after purchasing an additional 1,170 shares in the last quarter. FMR LLC boosted its holdings in argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares in the last quarter. Simplify Asset Management Inc. grew its stake in argenx by 64.0% in the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock valued at $1,311,000 after acquiring an additional 944 shares during the period. Ritholtz Wealth Management increased its holdings in shares of argenx by 85.5% during the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after acquiring an additional 414 shares in the last quarter. Finally, Westfield Capital Management Co. LP acquired a new position in shares of argenx during the third quarter worth approximately $571,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Up 0.5 %

ARGX traded up $3.49 during trading on Tuesday, hitting $642.90. 125,519 shares of the company traded hands, compared to its average volume of 260,808. The firm has a market cap of $39.06 billion, a P/E ratio of -730.57 and a beta of 0.58. argenx SE has a one year low of $349.86 and a one year high of $678.21. The stock's fifty day moving average is $640.16 and its 200 day moving average is $583.65.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ARGX shares. William Blair raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Friday, November 1st. Robert W. Baird cut shares of argenx from an "outperform" rating to a "neutral" rating and lifted their price objective for the company from $515.00 to $650.00 in a report on Friday, November 1st. Guggenheim upped their target price on shares of argenx from $585.00 to $665.00 and gave the stock a "buy" rating in a report on Friday, November 1st. Wolfe Research raised shares of argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price target on the stock in a research report on Tuesday, November 12th. Finally, Truist Financial reissued a "buy" rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, argenx presently has an average rating of "Moderate Buy" and an average price target of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.